NCT01245361View on ClinicalTrials.gov

A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2012

Conditions
Undifferentiated Arthritis
Interventions
DRUG

Infliximab

Infliximab 3 mg/kg wk 0,2,6

DRUG

sodium chloride

Group II : Placebo wk 0,2,6

Trial Locations (1)

1200

Université Catholique de Louvain, Brussels

All Listed Sponsors
lead

Patrick Durez

OTHER

NCT01245361 - A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit | Biotech Hunter | Biotech Hunter